It has been reported that the suppression of EZH2 in various malignant tumors like colorectal cancer (CRC) shifts TAMs toward the M1 phenotype via decreasing the H3K27me3 levels on the promoters of STAT3 (83), which is beneficial for tumor therapy, whereas a significantly decreased expression of EZH2 was found to be associated with adverse pregnancy outcomes such as RPL (84). This evidence concerns the gene EZH2 and cancer.